Irene Ghobrial, MD, is a Professor at the Dana-Farber Cancer Institute (DFCI), Harvard Medical School and an associate member of the Broad Institute. She is Director of the Michele & Stephen Kirsch Laboratory and co-director of the Center for Prevention of Progression (CPOP) at DFCI. Additionally, she is the co-leader of the Blood Cancer Research Partnership (BCRP), a consortium for innovative clinical trials of community oncology sites coordinated by DFCI. Dr. Ghobrial’s research focuses on understanding mechanisms of tumor progression from early precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering disease to symptomatic multiple myeloma and Waldenström Macroglobulinemia. She specifically focuses on the role of malignant bone marrow niche in regulating disease progression. She is interested in the development of new molecular/genomic markers that predict progression in precursor conditions which can identify patients who should be eligible for therapeutic interventions to prevent progression or potentially cure the disease at the early stages before clonal evolution occurs. She has authored or co-authored more than 250 publications and book chapters. She has received multiple awards including membership in the American Society of Clinical Investigation, the Robert A. Kyle Award for Research in Waldenström Macroglobulinemia, and the Mentor of the Year Award at DFCI in 2014. Dr. Ghobrial completed her hematology/oncology subspecialty training at the Mayo Clinic College of Medicine in Rochester, MN and internal medicine training at Wayne State University in Detroit, MI. She earned her medical degree from the Cairo School of Medicine in Egypt.

Dr. Tarek Mouhieddine is a physician–scientist and clinical investigator whose research focuses on understanding mechanisms of resistance to myeloma therapies, including CAR T cell therapy and bispecific antibodies, and developing novel therapeutic strategies to improve patient outcomes. He has a strong background in lab-based and translational research, with expertise in tumor genomics and the immune microenvironment. Dr. Mouhieddine is passionate about advancing precision cancer care, the early detection and interception of blood cancers, and translating laboratory discoveries into first-in-human phase I clinical trials in multiple myeloma.

Dr. Omar Nadeem completed his internal medicine residency training at Dartmouth-Hitchcock Medical Center and his hematology/oncology fellowship at the Warren Alpert Medical School of Brown University. He joined the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in 2018. He is an assistant professor at Harvard Medical School and serves as the Clinical Director of Myeloma Cellular Therapies Program and Medical Director of Center for Early Detection and Interception of Blood Cancers the Dana-Farber Cancer Institute. His clinical and research interests include studying the role of immunotherapy and cellular therapies in multiple myeloma, with particular focus on CAR T therapy. He serves as a principal investigator of several clinical trials in smoldering multiple myeloma, newly diagnosed disease and relapsed and refractory multiple myeloma.

Dr. Elizabeth (Betsy) O’Donnell received her medical degree from Vanderbilt University. She completed her residency in internal medicine at the Beth Israel Deaconess Medical Center where she served an additional year as a Chief Resident. She completed her fellowship in hematology and oncology at Dana-Farber Cancer Institute. She is the Director of Early Detection and Prevention at Dana-Farber and an Assistant Professor of Medicine at Harvard Medical School. She specializes in plasma cell disorders with a particular interest in lifestyle medicine and patient and caregiver quality of life.

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.